Does ALEMTUZUMAB Cause Mobility decreased? 229 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 229 reports of Mobility decreased have been filed in association with ALEMTUZUMAB (Campath). This represents 1.6% of all adverse event reports for ALEMTUZUMAB.
229
Reports of Mobility decreased with ALEMTUZUMAB
1.6%
of all ALEMTUZUMAB reports
7
Deaths
130
Hospitalizations
How Dangerous Is Mobility decreased From ALEMTUZUMAB?
Of the 229 reports, 7 (3.1%) resulted in death, 130 (56.8%) required hospitalization, and 9 (3.9%) were considered life-threatening.
Is Mobility decreased Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for ALEMTUZUMAB. However, 229 reports have been filed with the FAERS database.
What Other Side Effects Does ALEMTUZUMAB Cause?
Headache (1,808)
Fatigue (1,744)
Pyrexia (1,441)
Off label use (1,259)
Rash (1,094)
Nausea (1,053)
Dyspnoea (855)
Lymphocyte count decreased (852)
Asthenia (841)
Multiple sclerosis relapse (836)
What Other Drugs Cause Mobility decreased?
ADALIMUMAB (8,829)
ETANERCEPT (8,321)
METHOTREXATE (5,936)
ABATACEPT (4,519)
TOCILIZUMAB (4,403)
LEFLUNOMIDE (4,354)
HYDROXYCHLOROQUINE (4,105)
RITUXIMAB (4,067)
INFLIXIMAB (3,784)
TOFACITINIB (3,734)
Which ALEMTUZUMAB Alternatives Have Lower Mobility decreased Risk?
ALEMTUZUMAB vs ALENDRONATE
ALEMTUZUMAB vs ALENDRONATE\CHOLECALCIFEROL
ALEMTUZUMAB vs ALENDRONIC ACID
ALEMTUZUMAB vs ALEVE
ALEMTUZUMAB vs ALEVE CAPLET